The circulating transcriptome as a source of non-invasive cancer biomarkers: Concepts and controversies of non-coding and coding RNA in body fluids

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 10, 2015, Pages 2307-2323

  Fernandez Mercado, Marta ^a   Manterola, Lorea ^a   Larrea, Erika ^a   Goicoechea, Ibai ^a   Arestin, María ^a   Armesto, María ^a   Otaegui, David ^a   Lawrie, Charles H ^a,b,c  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Biological fluid; Biomarker; MicroRNA; NcRNA; Non invasive

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA 126; MICRORNA 145; MICRORNA 155; MICRORNA 21; MICRORNA 221; RNA; TRANSCRIPTOME; TRASTUZUMAB; UNTRANSLATED RNA; TUMOR MARKER;

ARTICLE; BIOPSY; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; DISEASE COURSE; EXTRACELLULAR FLUID; GENE EXPRESSION; GENOME; HUMAN; LUNG CANCER; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; ANIMAL; BLOOD; BODY FLUID; EXTRACELLULAR SPACE; GENETICS; METABOLISM;

ANIMALS; BIOMARKERS, TUMOR; BODY FLUIDS; EXTRACELLULAR SPACE; HUMANS; RNA, NEOPLASM; RNA, UNTRANSLATED; TRANSCRIPTOME;

EID: 84942357891     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12625     Document Type: Article

References (200)

1. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006; 52: 1833-42.
2. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer. 2003; 103: 149-52.
3. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil. 1948; 142: 241-3.
4. Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966; 45: 1732-40.
5. Ayala W, Moore LV, Hess EL. The purple color reaction given by diphenylamine reagent. I. With normal and rheumatic fever sera. J Clin Invest. 1951; 30: 781-5.
6. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37: 646-50.
7. Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994; 86: 774-9.
8. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994; 3: 67-71.
9. Lo KW, Lo YM, Leung SF, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999; 45: 1292-4.
10. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141: 672-5.
11. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34: D140-4.
12. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92-105.
13. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6: 376-85.
14. Lawrie CH. microRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? J Cell Mol Med. 2008; 12: 1432-44.
15. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27: 5848-56.
16. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8.
17. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007; 121: 1156-61.
18. Duttagupta R, Jiang R, Gollub J, et al. Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures. PLoS ONE. 2011; 6: e20769.
19. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105: 10513-8.
20. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006.
21. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101: 2087-92.
22. Lawrie CH. MicroRNA expression in lymphoma. Expert Opin Biol Ther. 2007; 7: 1363-74.
23. Schwarzenbach H, Pantel K. Circulating microRNAs as non-invasive biomarkers. In: Lawrie CH, editor. MicroRNAs in medicine. New York: Wiley; 2014. pp. 569-88.
24. Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119: 586-93.
25. Schwarzenbach H, Milde-Langosch K, Steinbach B, et al. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat. 2012; 134: 933-41.
26. Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011; 57: 84-91.
27. Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012; 10: 42.
28. Roth C, Rack B, Muller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010; 12: R90.
29. Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Molecular oncology. 2011; 5: 281-91.
30. Roth C, Kasimir-Bauer S, Heubner M, et al. Increase in circulating microRNA levels in blood of ovarian cancer patients. Adv Exp Med Biol Ed Gahan P Springer. 2010; 63-71.
31. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251: 499-505.
32. Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012; 118: 2603-14.
33. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012; 72: 1443-52.
34. Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012; 72: 1469-77.
35. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin. 2010; 42: 363-9.
36. Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011; 77: 1265.e9-16.
37. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012; 106: 768-74.
38. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011; 71: 326-31.
39. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011; 128: 608-16.
40. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE. 2011; 6: e17745.
41. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012; 36: e61-7.
42. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58: 1375-81.
43. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127: 118-26.
44. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25: 1674-80.
45. Yang IP, Tsai HL, Huang CW, et al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS ONE. 2013; 8: e66842.
46. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28: 1721-6.
47. Zhou C, Chen Z, Dong J, et al. Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer. Cancer Lett. 2015.
48. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17: 1298-307.
49. Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2012; 91: 553-9.
50. Chen W, Wang H, Chen H, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. Eur J Haematol. 2014; 92: 407-12.
51. Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS ONE. 2011; 6: e16408.
52. Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012; 2: e53.
53. Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE. 2009; 4: e5532.
54. Jones K, Nourse JP, Keane C, et al. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2014; 20: 253-64.
55. Guo HQ, Huang GL, Guo CC, et al. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis Markers. 2010; 29: 251-8.
56. Fayyad-Kazan H, Bitar N, Najar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013; 11: 31.
57. Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS ONE. 2013; 8: e56718.
58. Park NJ, Zhou X, Yu T, et al. Characterization of salivary RNA by cDNA library analysis. Arch Oral Biol. 2007; 52: 30-5.
59. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56: 1733-41.
60. Gallo A, Alevizos I. Isolation of circulating microRNA in saliva. Methods Mol Biol. 2013; 1024: 183-90.
61. Zimmermann BG, Wong DT. Salivary mRNA targets for cancer diagnostics. Oral Oncol. 2008; 44: 425-9.
62. Xie Z, Chen G, Zhang X, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS ONE. 2013; 8: e57502.
63. Matse JH, Yoshizawa J, Wang X, et al. Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors. Clin Cancer Res. 2013; 19: 3032-8.
64. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15: 5473-7.
65. Liu CJ, Lin SC, Yang CC, et al. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012; 34: 219-24.
66. Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004; 10: 8442-50.
67. Brinkmann O, Kastratovic DA, Dimitrijevic MV, et al. Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol. 2011; 47: 51-5.
68. Brogden KA, Chedid L, Cutlip RC, et al. Effect of muramyl dipeptide on immunogenicity of Corynebacterium pseudotuberculosis whole-cell vaccines in mice and lambs. Am J Vet Res. 1990; 51: 200-2.
69. Tang H, Wu Z, Zhang J, et al. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013; 7: 761-6.
70. Huang X, Liang M, Dittmar R, et al. Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci. 2013; 14: 14785-99.
71. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004; 64: 311-5; discussion 5-6.
72. Wang G, Kwan BC, Lai FM, et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers. 2010; 28: 79-86.
73. Snowdon J, Boag S, Feilotter H, et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2013; 7: 28-32.
74. Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer. 2013; 133: 2631-41.
75. Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012; 10: 106-13.
76. Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 2012; 107: 123-8.
77. Machida A, Ohkubo T, Yokota T. Circulating microRNAs in the cerebrospinal fluid of patients with brain diseases. Methods Mol Biol. 2013; 1024: 203-9.
78. Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012; 14: 689-700.
79. Gu YQ, Gong G, Xu ZL, et al. miRNA profiling reveals a potential role of milk stasis in breast carcinogenesis. Int J Mol Med. 2014; 33: 1243-9.
80. Tanaka Y, Tsuda S, Kunikata H, et al. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system. Sci Rep. 2014; 4: 5089.
81. Reddi KK, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci USA. 1976; 73: 2308-10.
82. Deligezer U, Erten N, Akisik EE, et al. Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol. 2006; 80: 72-6.
83. Kopreski MS, Benko FA, Kwak LW, et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999; 5: 1961-5.
84. Garcia V, Garcia JM, Pena C, et al. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008; 263: 312-20.
85. Silva J, Garcia V, Garcia JM, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Br Cancer Res. 2007; 9: R55.
86. March-Villalba JA, Martinez-Jabaloyas JM, Herrero MJ, et al. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS ONE. 2012; 7: e43470.
87. Deligezer U, Yaman F, Darendeliler E, et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta. 2010; 411: 1452-6.
88. Zheng T, Chen M, Han S, et al. Plasma minichromosome maintenance complex component 6 is a novel biomarker for hepatocellular carcinoma patients. Hepatol Res. 2014; 44: 1347-56.
89. Sun S, Xu MZ, Poon RT, et al. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res. 2010; 9: 70-8.
90. Dong ZZ, Yao DF, Yao M, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008; 7: 288-95.
91. Garcia V, Garcia JM, Silva J, et al. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS ONE. 2009; 4: e8173.
92. Whitney AR, Diehn M, Popper SJ, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA. 2003; 100: 1896-901.
93. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10: 155-9.
94. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12: 861-74.
95. Harries LW. Long non-coding RNAs and human disease. Biochem Soc Trans. 2012; 40: 902-6.
96. Xie C, Yuan J, Li H, et al. NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic Acids Res. 2014; 42: D98-103.
97. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol. 2011; 8: 123-4.
98. Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013; 49: 2949-59.
99. Isin M, Ozgur E, Cetin G, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014; 431: 255-9.
100. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. BioMed Res Int. 2013; 2013: 136106.
101. Rivas A, Burzio V, Landerer E, et al. Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer. BMC Urol. 2012; 12: 37.
102. Arita T, Ichikawa D, Konishi H, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013; 33: 3185-93.
103. Kumarswamy R, Bauters C, Volkmann I, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014; 114: 1569-75.
104. Kuhlmann JD, Baraniskin A, Hahn SA, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin Chem. 2014; 60: 206-13.
105. Liao J, Yu L, Mei Y, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer. 2010; 9: 198.
106. Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol. 2010; 28: e573-4; author reply e5-6.
107. Gourzones C, Ferrand FR, Amiel C, et al. Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients-evidence of non-exosomal transport. Virol J. 2013; 10: 119.
108. Hu J, Wang Z, Tan CJ, et al. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation. 2013; 95: 991-9.
109. Al-Soud WA, Radstrom P. Purification and characterization of PCR-inhibitory components in blood cells. J Clin Microbiol. 2001; 39: 485-93.
110. Garcia ME, Blanco JL, Caballero J, et al. Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol. 2002; 40: 1567-8.
111. Moldovan L, Batte K, Wang Y, et al. Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. Methods Mol Biol. 2013; 1024: 129-45.
112. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011; 57: 833-40.
113. Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE. 2011; 6: e24145.
114. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res. 2012; 5: 492-7.
115. Kroh EM, Parkin RK, Mitchell PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50: 298-301.
116. Kim YK, Yeo J, Kim B, et al. Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell. 2012; 46: 893-5.
117. Bernardo BC, Charchar FJ, Lin RC, et al. A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ. 2012; 21: 131-42.
118. Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomarkers Med. 2014; 8: 161-72.
119. Moldovan L, Batte KE, Trgovcich J, et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014; 18: 371-90.
120. Watson AK, Witwer KW. Do platform-specific factors explain microRNA profiling disparities? Clin Chem. 2012; 58: 472-4; author reply 4-5.
121. Dickinson B, Zhang Y, Petrick JS, et al. Lack of detectable oral bioavailability of plant microRNAs after feeding in mice. Nat Biotechnol. 2013; 31: 965-7.
122. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10: R64.
123. Sanders I, Holdenrieder S, Walgenbach-Brunagel G, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol. 2012; 19: 1017-25.
124. Hu J, Wang Z, Liao BY, et al. Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer. 2014; 135: 1187-94.
125. Wang Y, Tang N, Hui T, et al. Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. J Appl Toxicol. 2013; 33: 1330-6.
126. mcDermott AM, Kerin MJ, Miller N. Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS ONE. 2013; 8: e83718.
127. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE. 2009; 4: e6229.
128. Friedman EB, Shang S, Fleming NH, et al. Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients. J Biomed Sci Eng. 2012; 5: 647-51.
129. Murata K, Furu M, Yoshitomi H, et al. Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS ONE. 2013; 8: e69118.
130. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012; 37: 460-5.
131. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8: 467-77.
132. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39: 7223-33.
133. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009; 55: 1977-83.
134. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010; 3: 499-506.
135. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008; 3: e3694.
136. Ismail N, Wang Y, Dakhlallah D, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. 2013; 121: 984-95.
137. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9: 654-9.
138. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010; 38: 7248-59.
139. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13: 423-33.
140. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011; 108: 5003-8.
141. Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE. 2012; 7: e30679.
142. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011; 2: 282.
143. Baulcombe DC. RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants. Plant Mol Biol. 1996; 32: 79-88.
144. Turchinovich A, Samatov TR, Tonevitsky AG, et al. Circulating miRNAs: cell-cell communication function? Front Genet. 2013; 4: 119.
145. Thery C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011; 3: 15.
146. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470-6.
147. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 2010; 107: 6328-33.
148. Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS ONE. 2009; 4: e4722.
149. Yang M, Chen J, Su F, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011; 10: 117.
150. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011; 71: 5346-56.
151. Collino F, Grange C, Camussi G. Release of microRNA-containing vesicles can stimulate angiogenesis and metastasis in renal carcinoma. In: Lawrie CH, editor. MicroRNAs in medicine. New York: Wiley; 2014. pp. 607-22.
152. Umezu T, Ohyashiki K, Kuroda M, et al. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013; 32: 2747-55.
153. Williams Z, Ben-Dov IZ, Elias R, et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci USA. 2013; 110: 4255-60.
154. Zhang L, Hou D, Chen X, et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res. 2012; 22: 107-26.
155. Wang K, Li H, Yuan Y, et al. The complex exogenous RNA spectra in human plasma: an interface with human gut biota? PLoS ONE. 2012; 7: e51009.
156. Semenov DV, Baryakin DN, Brenner EV, et al. Unbiased approach to profile the variety of small non-coding RNA of human blood plasma with massively parallel sequencing technology. Expert Opin Biol Ther. 2012; 12(Suppl. 1): S43-51.
157. Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011; 124: 175-84.
158. Ronnau CG, Verhaegh GW, Luna-Velez MV, et al. Noncoding RNAs as novel biomarkers in prostate cancer. BioMed Res Int. 2014; 2014: 591703.
159. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012; 489: 101-8.
160. Alexander RP, Fang G, Rozowsky J, et al. Annotating non-coding regions of the genome. Nat Rev Genet. 2010; 11: 559-71.
161. Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010; 15: 673-82.
162. Kumar S, Keerthana R, Pazhanimuthu A, et al. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys. 2013; 50: 210-4.
163. Cuk K, Zucknick M, Madhavan D, et al. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS ONE. 2013; 8: e76729.
164. Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE. 2012; 7: e34210.
165. Zhu W, Qin W, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009; 2: 89.
166. Wang PY, Gong HT, Li BF, et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett. 2013; 6: 1681-6.
167. van Schooneveld E, Wouters MC, Van der Auwera I, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012; 14: R34.
168. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012; 72: 1443-52.
169. Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012; 72: 1469-77.
170. Baraniskin A, Nopel-Dunnebacke S, Ahrens M, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013; 132: E48-57.
171. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010; 102: 1174-9.
172. Komatsu S, Ichikawa D, Tsujiura M, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013; 33: 271-6.
173. Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: a potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 2013; 108: 89-92.
174. Maclellan SA, Lawson J, Baik J, et al. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med. 2012; 1: 268-74.
175. Liu CJ, Kao SY, Tu HF, et al. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010; 16: 360-4.
176. Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE. 2013; 8: e77853.
177. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009; 112: 55-9.
178. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110: 13-21.
179. Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2012; 12: 627.
180. Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013; 49: 3442-9.
181. Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers. 2009; 14: 529-38.
182. Panzitt K, Tschernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007; 132: 330-42.
183. Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2013; pii: S0378-1119(13)01419-4.
184. Wang RJ, Zheng YH, Wang P, et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015; 8: 765-71.
185. Wang P, Yang D, Zhang H, et al. Early detection of lung cancer in serum by a panel of microRNA biomarkers. Clin Lung Cancer. 2014; pii: S1525-7304(14)00271-X.
186. Hirajima S, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013; 108: 1822-9.
187. Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008; 14: 2588-92.
188. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013; 122: 1891-9.
189. Ilhan-Mutlu A, Wagner L, Wohrer A, et al. Plasma microRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest. 2012; 30: 615-21.
190. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2009; 2: 807-13.
191. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010; 3: 109-13.
192. Ganepola GA, Rutledge JR, Suman P, et al. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014; 6: 22-33.
193. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010; 28: 655-61.
194. Miyachi M, Tsuchiya K, Yoshida H, et al. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun. 2010; 400: 89-93.
195. Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012; 7: 1184-91.
196. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008; 3: e3148.
197. Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012; 41: 1871-8.
198. Cheng L, Sun X, Scicluna BJ, et al. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014; 86: 433-44.
199. Vasilescu C, Rossi S, Shimizu M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE. 2009; 4: e7405.
200. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011; 91: 579-87.